Ncardia Signs License Agreement with First Pharmaceutical Partner for Disease Modeling Patent Portfolio

COLOGNE, Germany–(BUSINESS WIRE)–#diseasemodel–Roche and Ncardia have reached a broad licensing agreement whereby Roche
and its affiliate companies gain access to key disease modeling patents
from Ncardia.


Ncardia was recently formed through the merger of Axiogenesis and
Pluriomics. The two companies have pioneered the development of stem
cell derived cells for drug discovery and safety and in particular have
advanced disease and tissue modeling applications.

The Ncardia patent portfolio consists of several granted patents in
Europe, the USA and Japan. The drug screening and disease modeling
technology not only involves patient iPSC cells, induction of the
disease phenotype can also be achieved through genetic manipulation,
mRNA or siRNA transfection or through chemical or physical induction.

Dr Stefan Braam, CEO Ncardia, commented: “Ncardia mission is to support
and enable our clients to make better medicines faster. The combination
of iPSC derived disease models with phenotypic screening is an extremely
powerful method to identify new drug candidates. This license marks a
further step in Ncardia technology strategy aimed at addressing the
potential of stem cell applications in the drug discovery and
development market.”

Roche has now obtained a non-exclusive, worldwide license to the key
Ncardia disease modeling patents claiming the use of stem cell derived
cells disease models for the discovery & development of novel drug
candidates. The financial terms of the agreements are not disclosed.

“This license is the first step of our strategy to make our technology
available to the pharmaceutical drug discovery & development market.”
Felix von Haniel VP Sales and BD of Ncardia. In addition to disease
modeling applications Ncardia is committed to providing the most
predictive healthy human cellular models to improve and accelerate
safety testing.

Ncardia: Ncardia (www.ncardia.com)
believes that stem cell technology will help to get better medicines to
patients faster. The company develops, produces and commercializes
highly predictive human cellular assay systems for safety and efficacy
testing. The cardiac product portfolio encompasses a broad panel of
hiPSC derived Cardiomyocytes (Pluricyte®, Cor.4U® and
vCor.4U) as well cardiac fibroblasts (FibroCor.4U).
In addition, the company delivers the Cardioplate product
line of quality controlled ready to use assay plates. The neural cell
portfolio contains the pan-neuronal product CNS.4U®, the
peripheral neurons product Peri.4U®, and astrocyte product
Astro.4U®.

Ncardia is committed to deliver its clients working assays solutions
through in house assay development and extensive support. The company
has a wide range of supported applications and compound assay services
such as of electrophysiology, biochemistry and contraction based assays
for predictive safety pharmacology and toxicology testing. In addition,
Ncardia develops and provides its customers with a broad portfolio of
cardiovascular services from disease modeling to cardiovascular drug
efficacy screening.

Ncardia is based in Belgium, the Netherlands, Germany and in the USA.
The company is privately held and established following the merger of
Pluriomics and Axiogenesis.

Contacts

Media:
Ncardia
Felix von Haniel
felix.haniel@ncardia.com